Corcept Therapeutics (FRA:HTD) Asset Impairment Charge: €0.0 Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:HTD Corcept Therapeutics Inc FRA:HTD
85 GF Score
Price €97.28
GF Value €60.85
Valuation Significantly Overvalued
! 9 Warning Signs
View Full Analysis

What is Corcept Therapeutics Asset Impairment Charge?

Corcept Therapeutics FRA:HTD -0.90% 85 Asset Impairment Charge is €0.0 Mil as of Jun. 2026. GuruFocus rates FRA:HTD with a GF Score™ of 85/100 and a GF Value™ of €60.85 (Significantly Overvalued). The stock has 9 warning signs investors should review.

Corcept Therapeutics's Asset Impairment Charge for the three months ended in Jun. 2026 was €0.0 Mil. Its Asset Impairment Charge for the trailing twelve months (TTM) ended in Jun. 2026 was €0.0 Mil.

Corcept Therapeutics Asset Impairment Charge Related Terms

Corcept Therapeutics Asset Impairment Charge Historical Data

* Premium members only.

The historical data trend for Corcept Therapeutics's Asset Impairment Charge can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Corcept Therapeutics Asset Impairment Charge Chart

Corcept Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Asset Impairment Charge
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Corcept Therapeutics Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Asset Impairment Charge Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
FRA:HTD
85GF Score
Corcept Therapeutics Inc FRA:HTD
Asset Impairment Charge is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Corcept Therapeutics Asset Impairment Charge Calculation

Asset Impairment Charge is the charge against earnings resulting from the aggregate write down of all assets from their carrying value to their fair value.

Asset Impairment Charge for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.0 Mil.

What does a Asset Impairment Charge of €0.0 Mil mean?
Corcept Therapeutics (FRA:HTD) has a Asset Impairment Charge of €0.0 Mil as of Jun. 2026.
Is Corcept Therapeutics' Asset Impairment Charge too high?
Corcept Therapeutics' current Asset Impairment Charge is €0.0 Mil. Overall, Corcept Therapeutics has a GF Score™ of 85/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Corcept Therapeutics' Asset Impairment Charge compare to MDGL and BMRN?
Corcept Therapeutics' Asset Impairment Charge of €0.0 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Asset Impairment Charge for a Biotechnology company?
A good Asset Impairment Charge depends on the Biotechnology industry context. However, Asset Impairment Charge should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Asset Impairment Charge mean?
A high Asset Impairment Charge can signal that a stock is expensive relative to its fundamentals. Corcept Therapeutics's current Asset Impairment Charge is €0.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Corcept Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Corcept Therapeutics (FRA:HTD) is currently considered Significantly Overvalued. The stock's GF Value™ is €60.85, compared to a current price of €97.28 — trading 59.9% above its estimated fair value. The current Asset Impairment Charge is €0.0 Mil. Corcept Therapeutics' overall GF Score™ is 85/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Asset Impairment Charge calculated?
Asset Impairment Charge is calculated from a company's financial statements. For Corcept Therapeutics (FRA:HTD), the current Asset Impairment Charge is €0.0 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Corcept Therapeutics (FRA:HTD) Overvalued in 2026?

Based on GuruFocus' analysis, Corcept Therapeutics stock appears to be overvalued. The current stock price of €97.28 is trading 59.9% above its estimated GF Value™ of €60.85. GuruFocus considers Corcept Therapeutics to be Significantly Overvalued.

Key valuation signals for FRA:HTD:

  • Asset Impairment Charge: €0.0 Mil
  • GF Value™: €60.85 vs. price of €97.28 (59.9% above fair value)
  • GF Score™: 85/100 with 9 warning signs

No single metric tells the full story. See the FRA:HTD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Corcept Therapeutics Business Description

Other Exchanges CORT:USA1CORT:Italy0I3Q:UK
Address 101 Redwood Shores Parkway, Redwood City, CA, USA, 94065
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic, and neuropsychiatric disorders by modulating the effect of the cortisol hormone. The company markets Korlym (mifepristone) tablets and its authorized generic version, which is an oral medication for the treatment of hypercortisolism (also known as Cushing's syndrome). Additionally, its pipeline contains several key compounds, such as Relacorilant, Dazucorilant, Miricorilant, etc., that are being evaluated in clinical trials as potential treatments for a variety of serious disorders like hypercortisolism, solid tumors (including ovarian, endometrial, cervical, pancreatic, and prostate cancers), ALS, and MASH.
85GF Score

Get the complete analysis for FRA:HTD

Asset Impairment Charge is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€97.28
Price
€60.85
GF Value